All In MedTech

FDA Clearance Tracker · P110042-S169

Subcutaneous Implantable Cardioverter Defibrillator (S-ICD)

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: May 18, 2022 (this decision)Source: openFDAMethods & limitations

PMA supplement

The decision

FDA number
P110042-S169
Device name
Subcutaneous Implantable Cardioverter Defibrillator (S-ICD)
Applicant location
St Paul, MN
Received
Apr 25, 2022
Decided
May 18, 2022
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Labeling Change - PAS
Original approval
P110042

Device type

Device class
Class III

Every decision under product code LWS

FDA's approval statement

As written in FDA's record.

Approval for updated labeling to include a clinical summary for the S-ICD Post Approval Study.

Source documents

Other decisions for Boston Scientific Corporation

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.